Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Raynaud

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 23, 2002
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]Frans Debruyne, Gary Koch, Peter Boyle, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 14, 2008
Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa)Frank Giton, Alexandre de la Taille, Yves Allory, et al.
BMC Nephrology|July 15, 2026
Kidney histopathology associated with kidney function at 1 year post severe AKI related to ANCA-associated vasculitisLéonard Cauchy, Pierre Raynaud, Pascal Reboul, et al.
European Urology|June 21, 2002
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyFrans Debruyne, Gary Koch, Peter Boyle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
European Urology|May 20, 2004
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisFrans Debruyne, Peter Boyle, Fernando Calais Da Silva, et al.
Oncogene|October 3, 2002
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arraysJohn De Vos, Thomas Thykjaer, Karin Tarte, et al.
Human Pathology|October 24, 2007
T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?Pierre Raynaud, Sylvie Caulet-Maugendre, Charles Foussard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysisMaud Condomines, Dirk Hose, Pierre Raynaud, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 23, 2002
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]Frans Debruyne, Gary Koch, Peter Boyle, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 14, 2008
Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa)Frank Giton, Alexandre de la Taille, Yves Allory, et al.
BMC Nephrology|July 15, 2026
Kidney histopathology associated with kidney function at 1 year post severe AKI related to ANCA-associated vasculitisLéonard Cauchy, Pierre Raynaud, Pascal Reboul, et al.
European Urology|June 21, 2002
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyFrans Debruyne, Gary Koch, Peter Boyle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
European Urology|May 20, 2004
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisFrans Debruyne, Peter Boyle, Fernando Calais Da Silva, et al.
Oncogene|October 3, 2002
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arraysJohn De Vos, Thomas Thykjaer, Karin Tarte, et al.
Human Pathology|October 24, 2007
T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?Pierre Raynaud, Sylvie Caulet-Maugendre, Charles Foussard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysisMaud Condomines, Dirk Hose, Pierre Raynaud, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Pageof 5